What happens in the first 48 hours

Leaving the clinic with a tender joint is entirely normal — and understanding what is happening inside it in the hours that follow makes those first two days considerably easier to manage.

The collagen solution sets into a soft scaffold within 3–5 minutes of being placed, bonding with the joint's natural fibrin as it does so. By the time the appointment is over, the material has already taken its intended shape. What the joint does next is simply biology: in the days and weeks that follow, the body's own progenitor cells begin to migrate into that scaffold and gradually differentiate into cartilage-forming cells. That repair process is already underway even while the joint is still sore.

Some soreness, swelling, and stiffness over the first day or two are a normal part of the inflammatory healing response — not a sign that something has gone wrong. Standard over-the-counter analgesia such as paracetamol or ibuprofen is appropriate for discomfort during this window, along with relative rest of the joint for the first one to two weeks while the scaffold stabilises.

It is worth setting expectations clearly from the outset: ChondroFiller is a regenerative scaffold that works through biological recruitment of the body's own cells, not an immediate pain-relief injection. Improvement typically becomes noticeable at six to twelve weeks, not in the first 48 hours.

Weeks 1–6: protecting the scaffold while repair begins

The most common question at this stage is a practical one: how soon can movement return to normal? For patients who have received ChondroFiller as an outpatient ultrasound-guided injection, clinical guidance typically indicates approximately 1–2 weeks of relative rest before returning to gentle movement — considerably shorter than the protection windows sometimes referenced in published cartilage-repair literature.

That distinction matters. References to a 4–6 week initial restriction relate to the arthroscopic surgical implantation route, not the outpatient injection pathway. The two should not be conflated when planning a return to daily activity.

Relative rest during this window does not mean complete immobility. Gentle, low-stress range-of-motion activity is generally encouraged throughout — keeping the joint moving supports integration of the collagen scaffold without placing excessive mechanical load on it while it stabilises. The protection phase is best understood as time for the scaffold to settle and bond with the surrounding tissue, rather than as a post-operative wound-healing restriction.

Structural repair established in the first hours continues throughout this period. The scaffold is actively recruiting the body's cells as it matures, even though perceived improvement — as noted — typically arrives later, between six and twelve weeks.

Weeks 6–12: when most people notice a difference

Six weeks in, many patients find themselves asking a version of the same question: is this actually working? That uncertainty is understandable — and it is precisely when the answer tends to change.

Published clinical evidence and London Cartilage Clinic's patient guidance both identify the window between six and twelve weeks as when most people first notice subjective improvement. ChondroFiller works through acellular matrix-induced chondrogenesis — the scaffold recruits the body's own progenitor cells, which differentiate progressively into cartilage-forming tissue. That is a biological timeline, not a pharmaceutical one, and it cannot be meaningfully accelerated. Feeling little different before week six is entirely consistent with normal scaffold biology, not a sign that the treatment has failed.

Physiotherapy typically begins during this phase, with the dual aim of restoring muscle strength and joint stability around the maturing scaffold. Low-impact activities such as cycling and swimming are commonly introduced alongside structured rehabilitation — both protect the joint from excessive load while supporting circulation and tissue development.

Importantly, twelve weeks is not the finish line. The scaffold continues to mature throughout the months that follow, and measurable improvements in function and comfort are expected to accumulate well beyond this initial milestone.

Months 2–6: rebuilding load and returning to activity

Around the two-month mark, the rehabilitation arc shifts meaningfully. The low-impact base established in weeks 6–12 — cycling, swimming, structured physiotherapy — gives way to progressively more purposeful loading, with activities such as jogging and directional sport-specific movement drills typically introduced during this window.

The word 'progressively' carries real weight here. Escalating activity too quickly risks placing mechanical stress on a scaffold that is still maturing and integrating with the surrounding tissue. Progression during months 2–6 is ideally symptom-guided rather than purely calendar-driven: if a joint is responding well to jogging, the next drill can be introduced; if it is reacting with sustained swelling or pain, that signals a need to consolidate rather than advance.

Continued physiotherapy involvement during this phase helps ensure that loading decisions are informed rather than instinctive. The treating team can adjust the pace based on how the joint is actually responding — something a fixed timetable cannot do.

Full sport and high-impact activity remain premature during this period for most patients. Contact sport, heavy loaded impact, and rapid changes of direction at competition intensity generally belong to the months 6–12 phase, once scaffold integration is more advanced. Individual variation is real: defect size, joint location, and baseline fitness all influence how quickly this transition unfolds.

Months 6–12 and beyond: return to sport and long-term tissue maturation

By months six to twelve, the focus shifts from protection and progressive loading to full participation in high-impact activity. For most patients, a gradual return to sport — including contact sport, heavy loaded movement, and rapid directional changes — is realistic within this window, though the pace depends on defect size, joint location, and individual response to rehabilitation. No fixed date applies universally.

Underpinning that return is a biological process that continues long after the joint feels normal again. Imaging assessments carried out at follow-up consistently show the scaffold gradually filling and consolidating over twelve months: in published studies, MOCART scores — a standardised measure of how well repair tissue has integrated on MRI — progress from around 65 at four weeks to approximately 82 at one year. Accompanying structural changes include reductions in bone marrow oedema, diminished joint effusion, and appearances consistent with consolidating repair tissue. These are objective markers of a process the patient cannot feel happening.

Functional scoring tells a parallel story. Measures of how the joint performs in daily life improve substantially across the first year — typically by around 30 points on validated knee assessments, which is well above the threshold considered clinically meaningful — and evidence from three-year follow-up in Jerosch et al.'s PMCF study suggests that improvement is sustained rather than eroded.

The scaffold itself is expected to be completely resorbed and replaced by the patient's own mature cartilage tissue by years one to two. That endpoint is the mechanism, not a promise: it is what the biology of acellular matrix-induced chondrogenesis is designed to achieve.

What the evidence shows — and where uncertainty remains

Published outcome data for ChondroFiller — the IKDC improvements of approximately 30 points, MOCART scores progressing to around 82 at twelve months, the sustained three-year results — derive predominantly from arthroscopic implantation studies rather than from the outpatient injection pathway. No standalone dataset exists for injection-delivered ChondroFiller specifically, so the milestones described in this article are a well-reasoned clinical framework rather than a precise individual forecast.

That distinction is about pathway-specificity, not efficacy doubt. The regenerative mechanism — acellular matrix-induced chondrogenesis, where the scaffold recruits the patient's own progenitor cells — operates in the same way regardless of how the scaffold is delivered. What the evidence base cannot yet confirm in granular detail is exactly how the phased surgical timeline translates to the injection-route experience.

Individual factors carry real weight as a result: defect size, joint location, age, activity level, and consistency of rehabilitation all shape recovery in ways that population averages cannot predict. Specialist assessment is the appropriate next step for anyone weighing ChondroFiller as an option — not a substitute for the clinical picture described here, but the means of applying it to a specific situation. Search MSK lists practitioners across the UK who offer ChondroFiller injection, searchable by region and specialty.